239 related articles for article (PubMed ID: 12591376)
1. Neoral (cyclosporine) C2 monitoring in renal transplant recipients: a single-center experience in Asia.
Wong HS; Morad Z
Transplant Proc; 2003 Feb; 35(1):230-1. PubMed ID: 12591376
[No Abstract] [Full Text] [Related]
2. Cyclosporine Neoral profiling in Japanese renal transplant recipients.
Aikawa A; Arai K; Tajima E; Kawamura T; Ogiwara H; Sakai K; Mizuiri S; Ohara T; Hasegawa A; Kosugi T; Kusano A; Matsuo K; Obayashi M; Kurokawa M
Transplant Proc; 2001; 33(7-8):3142-5. PubMed ID: 11750350
[No Abstract] [Full Text] [Related]
3. Role of postdose cyclosporine monitoring in living renal transplant recipients.
Thomas R; Minz M; Singh B; Heer M; Kashyap R
Transplant Proc; 2004 Sep; 36(7):2104. PubMed ID: 15518761
[TBL] [Abstract][Full Text] [Related]
4. C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients.
Citterio F; Scatà MC; Borzi MT; Pozzetto U; Castagneto M
Transplant Proc; 2001; 33(7-8):3133-6. PubMed ID: 11750347
[No Abstract] [Full Text] [Related]
5. Optimization of cyclosporine therapy with abbreviated area under the curve method in renal transplant.
Yang WC; Chen YF; King KL; Wu TH; Chen Hsu RY ; Tang JJ; Loong CC; Chou MH; Lin MF; Lui WY
Transplant Proc; 2000 Nov; 32(7):1685-7. PubMed ID: 11119892
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics, efficacy, and safety of Iminoral compared with Neoral in healthy volunteers and renal transplant recipients.
Sayyah M; Argani H; Pourmand GR; Amini H; Ahmadiani A
Transplant Proc; 2007 May; 39(4):1214-8. PubMed ID: 17524936
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine A: peak or trough level monitoring in renal transplant recipients?
Wacke R; Drewelow B; Kundt G; Hehl EM; Bast R; Seiter H
Transplant Proc; 2001; 33(7-8):3122-3. PubMed ID: 11750342
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
Zhang Y; Zhang XD; Wang Y
Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
[TBL] [Abstract][Full Text] [Related]
9. Neoral C2 monitoring in solid organ transplantation.
Levy GA
Transplant Proc; 2004 Mar; 36(2 Suppl):392S-395S. PubMed ID: 15041373
[No Abstract] [Full Text] [Related]
10. High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome.
Cicciarelli J; Avila D; Iwaki Y; Sather H; Mendez R
Transplant Proc; 1998 Aug; 30(5):1683-4. PubMed ID: 9723243
[No Abstract] [Full Text] [Related]
11. Conversion of C-0 to C-2 monitoring of cyclosporine in stable kidney transplant patients.
Jirasiritham S; Mavichak V; Danviriyasup K; Jirasiritham S
Transplant Proc; 2003 Feb; 35(1):236-7. PubMed ID: 12591379
[No Abstract] [Full Text] [Related]
12. Greater variability of dose-corrected cyclosporine C2 concentrations in renal recipients with acute rejection.
Chueh SC; Liao CH; Lai MK
Transplant Proc; 2003 Feb; 35(1):234-5. PubMed ID: 12591378
[No Abstract] [Full Text] [Related]
13. Experience with conversion from Sandimmun to Neoral cyclosporine and the correlation of C2 levels with renal function.
Konstadinidou I; Boletis JN
Transplant Proc; 2004 Mar; 36(2 Suppl):163S-166S. PubMed ID: 15041329
[TBL] [Abstract][Full Text] [Related]
14. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.
Vathsala A; Lu YM
Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348
[No Abstract] [Full Text] [Related]
15. Conversion from Sandimmune to Neoral in renal transplant: functional histopathological, and pharmacokinetic changes.
Roessler E; Herrera S; Espinoza M; Ayala A; Reynolds E; González F; Espinoza O; Undurraga A; Muñoz R; Arcos O; Galaz G
Transplant Proc; 1998 Aug; 30(5):1756-7. PubMed ID: 9723268
[No Abstract] [Full Text] [Related]
16. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2.
Cole E; Deshpande R
Transplant Proc; 2004 Mar; 36(2 Suppl):408S-413S. PubMed ID: 15041376
[TBL] [Abstract][Full Text] [Related]
17. C0/C2 cyclosporine levels monitoring in renal transplantation.
Santana A; Guerra J; Milhomens C; Neves F; Prata MM
Transplant Proc; 2003 May; 35(3):1072-3. PubMed ID: 12947862
[No Abstract] [Full Text] [Related]
18. Can three-times-a-day cyclosporine Neoral avoid cyclosporine toxicity in renal transplant recipients? A pharmacokinetic study.
Swart N; Botha J; Tandon V; Michaels P; Pontin AR; Halkett J; Pascoe MD; Kahn D
Transplant Proc; 2001; 33(7-8):3140-1. PubMed ID: 11750349
[No Abstract] [Full Text] [Related]
19. Conversion from Sandimmune to Neoral in renal transplant recipients: two-year experience.
Wilczek HE; Akesson P; Warholm C
Transplant Proc; 1998 Aug; 30(5):1753-5. PubMed ID: 9723267
[No Abstract] [Full Text] [Related]
20. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method.
First MR; Weiskittel P; Burton M; Shah M; Dreyer D; Fleck P; Bey C; Peddi R; Canafax D; Schroeder TJ
Transplant Proc; 1998 Aug; 30(5):1701-5. PubMed ID: 9723249
[No Abstract] [Full Text] [Related]
[Next] [New Search]
